Q2 EPS Forecast for Bausch Health Companies Cut by Analyst

Bausch Health Companies Inc. (TSE:BHC - Free Report) - Analysts at Zacks Research reduced their Q2 2026 EPS estimates for Bausch Health Companies in a research note issued to investors on Wednesday, May 21st. Zacks Research analyst R. Department now anticipates that the company will post earnings per share of $1.34 for the quarter, down from their previous forecast of $1.59. The consensus estimate for Bausch Health Companies' current full-year earnings is $5.55 per share. Zacks Research also issued estimates for Bausch Health Companies' Q4 2026 earnings at $1.55 EPS.

Bausch Health Companies Stock Performance

TSE:BHC traded up C$0.12 on Friday, hitting C$6.35. The stock had a trading volume of 289,000 shares, compared to its average volume of 344,297. Bausch Health Companies has a 52-week low of C$5.45 and a 52-week high of C$13.74. The stock has a market cap of C$1.65 billion, a price-to-earnings ratio of -9.29, a price-to-earnings-growth ratio of 0.21 and a beta of 0.77. The company has a quick ratio of 0.58, a current ratio of 1.19 and a debt-to-equity ratio of -1,831.94. The business's 50-day simple moving average is C$7.37 and its two-hundred day simple moving average is C$9.61.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.